Innovation and Biomarkers in Cancer Drug Development: A Joint Meeting Presented By EORTC, NCI, EMA, and AACR

​Nov. 29-30, 2018
Radisson Blu Royal Hotel
Brussels, Belgium

Registration Deadline: Thursday, Nov. 15, 2018 (now open)

Organizing Committee Chairs
Denis A. Lacombe, European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium
Roberto Salgado, GasthuisZusters Antwerp (GZA), Antwerp, Belgium

Organizing Committee Cochairs
Jonas C. S. Bergh, Karolinska Institute University Hospital, Stockholm, Sweden
Michael A. Caligiuri, James Cancer Hospital & Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Lyndsay N. Harris, National Institutes of Health, Rockville, Maryland
Tracy G. Lively, National Cancer Institute, Rockville, Maryland
Francesco Pignatti, The European Medicines Agency (EMA), London, England
Victor E. Velculescu, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland

Never before has cancer drug and biomarker development been so complex and required such a diverse range of expertise. Following the success of the IBCD2016 program in Brussels, the EORTC, NCI, EMA, and AACR are once again collaborating on a unique program with the intention of stimulating the dialog between those conducting clinical trials and those working in the laboratory. This unique program will spotlight multi-stakeholder approaches to cancer drug development with new cancer biomarkers. Plenary lectures and panel discussions will include key opinion leaders representing regulators, payers, industry, patients, and academia in order to enhance collaborations needed for developing improved treatments for patients with cancer.